Yarrow Bioscience, Inc. (YARW)
18.40
+0.47
(+2.62%)
USD |
NASDAQ |
Nov 03, 15:56
Yarrow Bioscience Enterprise Value : -10.94M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | -10.94M |
| October 30, 2026 | -9.626M |
| October 29, 2026 | -9.559M |
| October 28, 2026 | -9.846M |
| October 27, 2026 | -9.479M |
| October 26, 2026 | -9.559M |
| October 23, 2026 | -10.05M |
| October 22, 2026 | -9.826M |
| October 21, 2026 | -9.445M |
| October 20, 2026 | -9.419M |
| October 19, 2026 | -9.572M |
| October 16, 2026 | -10.69M |
| October 15, 2026 | -9.559M |
| October 14, 2026 | -10.29M |
| October 13, 2026 | -10.49M |
| October 12, 2026 | -9.679M |
| October 09, 2026 | -9.753M |
| October 08, 2026 | -9.646M |
| October 07, 2026 | -10.38M |
| October 06, 2026 | -10.41M |
| October 05, 2026 | -9.358M |
| October 02, 2026 | -8.042M |
| October 01, 2026 | -7.153M |
| September 30, 2026 | -7.875M |
| September 29, 2026 | -6.759M |
| Date | Value |
|---|---|
| September 28, 2026 | -6.886M |
| September 25, 2026 | -5.857M |
| September 24, 2026 | -5.502M |
| September 23, 2026 | -4.293M |
| September 22, 2026 | -3.758M |
| September 21, 2026 | -4.012M |
| September 18, 2026 | -3.350M |
| September 17, 2026 | -2.488M |
| September 16, 2026 | -5.589M |
| September 15, 2026 | -5.883M |
| September 14, 2026 | -5.375M |
| September 11, 2026 | -4.874M |
| September 10, 2026 | -3.918M |
| September 09, 2026 | -3.471M |
| September 08, 2026 | -3.344M |
| September 04, 2026 | -2.736M |
| September 03, 2026 | -3.644M |
| September 02, 2026 | -2.889M |
| September 01, 2026 | -2.221M |
| August 31, 2026 | -0.8978M |
| August 28, 2026 | 1.802M |
| August 27, 2026 | 2.470M |
| August 26, 2026 | 3.563M |
| August 25, 2026 | 3.306M |
| August 24, 2026 | 3.473M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cypherpunk Technologies, Inc. | 246.74M |
| Cue Biopharma, Inc. | 92.97M |
| Faeth Therapeutics, Inc. | 317.69M |
| Indaptus Therapeutics, Inc. | 454.79M |
| Pyxis Oncology, Inc. | 90.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.899M |
| Revenue (Quarterly) | 0.097M |
| Total Expenses (Quarterly) | 2.996M |
| EPS Diluted (Quarterly) | -3.504 |
| Gross Profit Margin (Quarterly) | 93.81% |
| Profit Margin (Quarterly) | -2.99K% |
| Earnings Yield | -127.5% |
| Normalized Earnings Yield | -127.49 |